Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 233

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Berberine decreases PCSK9 expression in HepG2 cells

Cameron, Jamie, Ranheim, Trine, Kulseth, Mari Ann, Leren, Trond P., Berge, Knut Erik·2008·Atherosclerosis
DOI 10.1016/j.atherosclerosis.2008.02.004
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.atherosclerosis.2008.02.004

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 25

  1. Keys, 1971, Mortality and coronary heart disease among men studied for 23 years, Arch Intern Med, 128, 201, 10.1001/archinte.128.2.201 · DOI · Paper page
  2. The Scandinavian Simvastatin Survival Study Group, 1994, Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S), Lancet, 344, 1383
  3. Dubuc, 2004, Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia, Arterioscler Thromb Vasc Biol, 24, 1454, 10.1161/01.ATV.0000134621.14315.43 · DOI · Paper page
  4. Abifadel, 2003, Mutations in PCSK9 cause autosomal dominant hypercholesterolemia, Nat Genet, 34, 154, 10.1038/ng1161 · DOI · Paper page
  5. Cunningham, 2007, Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia, Nat Struct Mol Biol, 14, 413, 10.1038/nsmb1235 · DOI · Paper page
  6. Fisher, 2007, Effects of pH and low density lipoprotein (LDL) on PCSK9-dependent LDL receptor regulation, J Biol Chem, 282, 20502, 10.1074/jbc.M701634200 · DOI · Paper page
  7. Benjannet, 2006, The proprotein convertase PCSK9 is inactivated by furin and/or PC5/6A: functional consequences of natural mutations and post-translational modifications, J Biol Chem, 10.1074/jbc.M606495200 · DOI · Paper page
  8. Rashid, 2005, Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9, Proc Natl Acad Sci USA, 102, 5374, 10.1073/pnas.0501652102 · DOI · Paper page
  9. Zhao, 2006, Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote, Am J Hum Genet, 79, 514, 10.1086/507488 · DOI · Paper page
  10. Choi, 2006, Berberine reduces the expression of adipogenic enzymes and inflammatory molecules of 3T3-L1 adipocyte, Exp Mol Med, 38, 599, 10.1038/emm.2006.71 · DOI
  11. Hwang, 2006, Berberine induces apoptosis through a mitochondria/caspases pathway in human hepatoma cells, Arch Toxicol, 80, 62, 10.1007/s00204-005-0014-8 · DOI
  12. Zhou, 2007, Berberine stimulates glucose transport through a mechanism distinct from insulin, Metabolism, 56, 405, 10.1016/j.metabol.2006.10.025 · DOI
  13. Lin, 2006, Down-regulation of cyclin B1 and up-regulation of Wee1 by berberine promotes entry of leukemia cells into the G2/M-phase of the cell cycle, Anticancer Res, 26, 1097
  14. Tang, 2006, Effects of berberine on diabetes induced by alloxan and a high-fat/high-cholesterol diet in rats, J Ethnopharmacol, 108, 109, 10.1016/j.jep.2006.04.019 · DOI · Paper page
  15. Jantova, 2006, Photochemical and phototoxic activity of berberine on murine fibroblast NIH-3T3 and Ehrlich ascites carcinoma cells, J Photochem Photobiol B, 85, 163, 10.1016/j.jphotobiol.2006.07.001 · DOI
  16. Abidi, 2005, Extracellular signal-regulated kinase-dependent stabilization of hepatic low-density lipoprotein receptor mRNA by herbal medicine berberine, Arterioscler Thromb Vasc Biol, 25, 2170, 10.1161/01.ATV.0000181761.16341.2b · DOI · Paper page
  17. Cicero, 2007, Eulipidemic effects of berberine administered alone or in combination with other natural cholesterol-lowering agents. A single-blind clinical investigation, Arzneimittelforschung, 57, 26
  18. Lee, 2007, Berberine-induced LDLR up-regulation involves JNK pathway, Biochem Biophys Res Commun, 362, 853, 10.1016/j.bbrc.2007.08.060 · DOI
  19. Holla, 2006, Low-density lipoprotein receptor activity in Epstein–Barr virus-transformed lymphocytes from heterozygotes for the D374Y mutation in the PCSK9 gene, Scand J Clin Lab Invest, 66, 317, 10.1080/00365510600672775 · DOI
  20. Holla, 2007, Degradation of the LDL receptors by PCSK9 is not mediated by a secreted protein acted upon by PCSK9 extracellularly, BMC Cell Biol, 8, 9, 10.1186/1471-2121-8-9 · DOI
  21. Costet, 2006, Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c, J Biol Chem, 281, 6211, 10.1074/jbc.M508582200 · DOI · Paper page
  22. Peschel, 2007, Curcumin induces changes in expression of genes involved in cholesterol homeostasis, J Nutr Biochem, 18, 113, 10.1016/j.jnutbio.2006.03.007 · DOI
  23. Careskey, 2008, Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9, J Lipid Res, 49, 394, 10.1194/jlr.M700437-JLR200 · DOI · Paper page
  24. Wang, 2007, Studies on alkaloids binding to GC-rich human survivin promoter DNA using positive and negative ion electrospray ionization mass spectrometry, J Mass Spectrom
  25. Lambert, 2006, Fasting induces hyperlipidemia in mice overexpressing PCSK9: lack of modulation of VLDL hepatic output by the LDLr, Endocrinology, 10.1210/en.2006-0098 · DOI

Cited by

See all 233

Metadata

Authors
Cameron, J., Ranheim, T., Kulseth, M. A., Leren, T. P., & Berge, K. E.
Venue
Atherosclerosis
Publisher
Elsevier BV
Published
2008-12
Volume
201
Issue
2
Pages
266-273
ISSN
0021-9150 (ISSN-L)
DOI
10.1016/j.atherosclerosis.2008.02.004
OpenAlex
W2011857098
Cited by
233
References
4
FWCI
6.46
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.